BioWorld

Jan. 16, 2008

XenoPort's RLS Drug Reduces Relapse Rate In Phase III Trial

Genentech Earnings Just OK, 'Flattish' 2008 Ahead: Analyst

Pervasis Gets $9.75M to Boost Blood Vessel Repair Candidate

Alfacell Deals U.S. Rights for Onconase to Strativa

Alfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million. (BioWorld Today) Read More

Novo Nordisk Halts Development of its Inhaled Insulin Program

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists

BioWorld Science

Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.